Human α7 Integrin Gene ( ITGA7 ) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice
- 1 October 2015
- journal article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 26 (10) , 647-656
Abstract
Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene. It is the most common, severe childhood form of muscular dystrophy. We investigated an alternative to dystrophin replacement by overexpressing ITGA7 using adeno-associated virus (AAV) delivery. ITGA7 is a laminin receptor in skeletal muscle that, like the dystrophin-glycoprotein complex, links the extracellular matrix to the internal actin cytoskeleton. ITGA7 is expressed in DMD patients and overexpression does not elicit an immune response to the transgene. We delivered rAAVrh.74.MCK.ITGA7 systemically at 5-7 days of age to the mdx/utrn(-/-) mouse deficient for dystrophin and utrophin, a severe mouse model of DMD. At 8 weeks postinjection, widespread expression of ITGA7 was observed at the sarcolemma of multiple muscle groups following gene transfer. The increased expression of ITGA7 significantly extended longevity and reduced common features of the mdx/utrn(-/-) mouse, including kyphosis. Overexpression of α7 expression protected against loss of force following contraction-induced damage and increased specific force in the diaphragm and EDL muscles 8 weeks after gene transfer. Taken together, these results further support the use of α7 integrin as a potential therapy for DMD.Keywords
This publication has 25 references indexed in Scilit:
- Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene TransferPLOS ONE, 2012
- Evidence‐based path to newborn screening for duchenne muscular dystrophyAnnals of Neurology, 2012
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- Persistent Expression of FLAG-tagged Micro dystrophin in Nonhuman Primates Following Intramuscular and Vascular DeliveryMolecular Therapy, 2010
- A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophyJournal of Translational Medicine, 2007
- Design of Tissue-specific Regulatory Cassettes for High-level rAAV-mediated Expression in Skeletal and Cardiac MuscleMolecular Therapy, 2007
- Adeno-Associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injuryMolecular Therapy, 2005
- Progression of kyphosis in mdx miceJournal of Applied Physiology, 2004
- Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular DystrophyNew England Journal of Medicine, 1989
- Clinical investigation in duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural historyMuscle & Nerve, 1983